Borderline Pancreas Study: FOLFIRINOX +SBRT

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 27, 2018

Study Completion Date

September 27, 2018

Conditions
Resectable Pancreatic Cancer
Interventions
OTHER

Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable

Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.

DRUG

-Oxaliplatin 85 mg/m2 IV on Day 1

Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).

DRUG

-Irinotecan 180 mg/m2 IV on Day 1

Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).

DRUG

-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours

5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.

Trial Locations (1)

21201

University of Maryland Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT01992705 - Borderline Pancreas Study: FOLFIRINOX +SBRT | Biotech Hunter | Biotech Hunter